Drug Information

Drug General Information
Drug ID
D0Y3XB
Former ID
DNC001208
Drug Name
RhuCD40L
Indication Discovery agent Terminated [546452]
Target and Pathway
Target(s) Tumor necrosisfactor receptor superfamily member 5 Target Info Binder [535281]
KEGG Pathway Cytokine-cytokine receptor interaction
NF-kappa B signaling pathway
Cell adhesion molecules (CAMs)
Toll-like receptor signaling pathway
Intestinal immune network for IgA production
Malaria
Toxoplasmosis
HTLV-I infection
Epstein-Barr virus infection
Transcriptional misregulation in cancer
Asthma
Autoimmune thyroid disease
Systemic lupus erythematosus
Allograft rejection
Primary immunodeficiency
Viral myocarditis
Pathway Interaction Database CD40/CD40L signaling
WikiPathways Toll-like receptor signaling pathway
Inflammatory Response Pathway
NLR Proteins
Vitamin D Receptor Pathway
Human Complement System
Allograft Rejection
Regulation of toll-like receptor signaling pathway
References
Ref 546452Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008196)
Ref 535281Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 2001 Oct 15;61(20):7556-62.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.